FirsthandHealth
medRxiv PreprintsInternational20 November 2026

Circulating gelsolin tracks disease stage in amyotrophic lateral sclerosis across four cohorts

This is an official announcement record

Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.

Amyotrophic lateral sclerosis is a fatal neurodegenerative disease with highly variable survival, and blood biomarkers beyond neurofilament light chain (NfL) are needed for prognosis and trial stratification. A biomarker of progress through an individualised disease course may be prognostic but independent of the rate of neurodegeneration. We analysed the serum proteome (5,401 proteins) and plasma and cerebrospinal fluid metabolomes (1,659 metabolites) of 94 patients with amyotrophic lateral sclerosis and 39 controls recruited in Sheffield, UK, and replicated findings in cohorts from Tel Aviv,
Source: medRxiv Preprints
Read the official announcement

Opens www.medrxiv.org

More from medRxiv Preprints

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.